Tuesday, April 13, 2021

FDA Halts Use of Johnson & Johnson COVID Vaccine Due to Blood Clotting


The Food and Drug Administration said this morning that it is asking states to temporarily halt using Johnson & Johnson’s Covid-19 vaccine “out of an abundance of caution” after six women in the U.S. developed a rare blood clotting disorder.

“Right now, these adverse events appear to be extremely rare,” the FDA said in a joint statement with the Centers for Disease Control and Prevention. “COVID-19 vaccine safety is a top priority for the federal government, and we take all reports of health problems following COVID-19 vaccination very seriously.”

All six cases occurred in women between the ages of 18 and 48, with symptoms developing six to 13 days after they received the shot.

The CDC will convene a meeting of the Advisory Committee on Immunization Practices on Wednesday to further review the cases, federal health regulators said Tuesday. The FDA is also investigating the cases.

Last week, Europe’s medicines regulator said it found a possible link between the coronavirus vaccine developed by AstraZeneca and the University of Oxford and rare blood clotting issues. AstraZeneca has not received authorization for use in the U.S.




  1. Uhm.... Well, the NIH co-owns the patent on the Moderna shot (sic), so competition is not welcome. That's my initial take. Oh, and J&J have never brought a 'vaccine' to market. Ever.

    There's a reason no coronavirus vaccine has never been brought to market. And never will. (I'm withholding judgement on the Sputnik V. I haven't seen the numbers.)

    As for the mRNA (technology - sic), it's not a vaccine - even in its supposed secondary action of producing a spiked protein - and never will be.

    1. Sputnik V is similar to J&J, only augmented with use of two different adenovirus vectors at two stages to reduce immune reaction to the vector virus after the second shot.

  2. Are there grounds for fraud labeling a product a "Vaccine" when it's not legally a vaccine?